SCHEMBL2916304

SCHEMBL2916304

CCCCCCC1C(=O)OC1CCCCCOCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G6 O60733 2/20 0.60
PLA2G4A P47712 1/20 0.60
DAGLA Q9Y4D2 3/20 0.52
LYPLA1 O75608 3/20 0.51
LYPLA2 O95372 3/20 0.51
ABHD16A O95870 1/20 0.51
PNLIP P16233 3/20 0.46
FASN P49327 1/20 0.46
PTPN1 P18031 1/20 0.43
CDC25B P30305 1/20 0.43
NAAA Q02083 1/20 0.42
PRKCA P17252 3/20 0.42
PRKD3 O94806 1/20 0.42
PRKCG P05129 1/20 0.42
PRKCB P05771 1/20 0.42
PRKCH P24723 1/20 0.42
PRKCE Q02156 1/20 0.42
PRKCQ Q04759 1/20 0.42
PRKCD Q05655 1/20 0.42
PRKD1 Q15139 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448340 1.00 PLA2G6 (0.60) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2
SCHEMBL2916300 1.00 PLA2G6 (0.60) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2
SCHEMBL2916334 0.87 FASN (0.61) PLA2G6PLA2G4ADAGLAFASNNAAA
SCHEMBL2916335 0.87 FASN (0.61) PLA2G6PLA2G4ADAGLAFASNNAAA
SCHEMBL2916331 0.87 FASN (0.61) PLA2G6PLA2G4ADAGLAFASNNAAA
SCHEMBL19514903 0.83 PLA2G6 (0.84) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2
SCHEMBL19514898 0.83 PLA2G6 (0.84) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2
SCHEMBL19514935 0.83 PLA2G6 (0.84) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2
SCHEMBL19514905 0.83 PLA2G6 (0.84) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2
SCHEMBL17979630 0.83 PLA2G6 (0.80) PLA2G6PLA2G4ADAGLALYPLA1LYPLA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-08 US claimed
EP-1751126-B1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS ABBOTT PRODUCTS GMBH (DE) 2010-09-01 EP disclosed
EP-1751126-A1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS Solvay Pharmaceuticals GmbH (DE) 2007-02-14 EP disclosed
US-7074822-B2 Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2006-07-11 US disclosed
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-08 US disclosed
WO-2005080366-A1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them PNLIP, CEL, LIPE PLA2G6 193/4885PLA2G4A 198/4885DAGLA 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.